Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12098-023-04945-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pleuropulmonary blastoma (PPB) with central nervous system metastasis: case report, imaging findings, and review of literature.
Acta Chir Belg
December 2024
University Children's Hospital, Belgrade, Serbia.
Article Synopsis
- Pleuropulmonary blastoma (PPB) is a rare lung tumor primarily affecting young children, categorized into three types based on its characteristics, with a poor prognosis overall.* -
- A case study showcased a type 2 PPB that initially presented as a pulmonary abscess, highlighting the need for awareness in similar presentations, especially in children with oncological family histories.* -
- The authors emphasize the significance of understanding PPB's genetic and biological nature to improve treatment options, including innovations in therapies and the potential role of artificial intelligence in diagnosis.*
Flash Pleural Effusion in a Post-Operative Case of Hypothalamic Hamartoma : Is it Due to Autonomic Havoc?
Indian J Pediatr
May 2024
Department of Neurology, Room no 602, CN Centre, AIIMS, New Delhi, 110029, India.
Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma.
Nat Commun
May 2023
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Malignant pleural mesothelioma (MPM) has relatively ineffective first/second-line therapy for advanced disease and only 18% five-year survival for early disease. Drug-induced mitochondrial priming measured by dynamic BH3 profiling identifies efficacious drugs in multiple disease settings. We use high throughput dynamic BH3 profiling (HTDBP) to identify drug combinations that prime primary MPM cells derived from patient tumors, which also prime patient derived xenograft (PDX) models.
View Article and Find Full Text PDFDevelopment and validation of qualitative and quantitative models to predict invasiveness of lung adenocarcinomas manifesting as pure ground-glass nodules based on low-dose computed tomography during lung cancer screening.
Quant Imaging Med Surg
May 2022
Department of Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Background: Due to different management strategy and prognosis of different subtypes of lung adenocarcinomas appearing as pure ground-glass nodules (pGGNs), it is important to differentiate invasive adenocarcinoma (IA) from adenocarcinoma in situ/minimally invasive adenocarcinoma (AIS/MIA) during lung cancer screening. The aim of this study was to develop and validate the qualitative and quantitative models to predict the invasiveness of lung adenocarcinoma appearing as pGGNs based on low-dose computed tomography (LDCT) and compare their diagnostic performance with that of intraoperative frozen section (FS).
Methods: A total of 223 consecutive pathologically confirmed pGGNs from March 2018 to December 2020 were divided into a primary cohort (96 IAs and 64 AIS/MIAs) and validation cohort (39 IAs and 24 AIS/MIAs) according to scans (Brilliance iCT and Somatom Definition Flash) performed at Sichuan Cancer Hospital and Institute.
Priorities, actions and risks in the COVID-19 pandemic: a flash SoMe survey among surgical oncologists.
Pleura Peritoneum
March 2021
Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Lausanne, Switzerland.
Objectives: Corona virus-induced disease 19 (COVID-19) pandemic has globally affected the surgical treatment of cancer patients and has challenged the ethical principles of surgical oncologists around the world. Not only treatment but also diagnosis and follow-up have been disrupted.
Methods: An online survey was sent through Twitter and by the surgical societies worldwide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!